

## Urgent Field Safety Notice

**ACHC20-01.A.OUS**

**December 2019**

### Atellica CH® Analyzer

### Phenindione Interference with Enzymatic Creatinine (ECre\_2) and Japan Enzymatic Creatinine (ECreJ) Assays

Our records indicate that your facility may have received the following product:

**Table 1. Atellica CH Products affected by Phenindione**

Assay	Test Code	REF Number	Siemens Material Number (SMN)	Lot Number
Enzymatic Creatinine_2	ECre_2	11097533	11097533	All
Japan Enzymatic Creatinine	ECreJ	11319121 (Japan only)	11319121 (Japan only)	

### Reason for Correction

The purpose of this communication is to inform you of an issue with the product indicated in Table 1 above and provide instructions on actions that your laboratory must take.

Siemens Healthcare Diagnostics has become aware of reports of falsely depressed creatinine results for patients on phenindione therapy when using the enzymatic methodology. Interference has not been observed with the creatinine Jaffe methodology.

Phenindione is a vitamin K antagonist that acts as an anticoagulant. Phenindione therapy is no longer broadly prescribed due to known adverse side effects. Phenindione may be used if alternative anticoagulants are unavailable or not suitable for a patient.

Phenindione and/or phenindione metabolites are likely to play a significant role in the interference effect observed in samples from patients on phenindione therapy.

The “Limitations” sections of the Instructions For Use (IFU) for the Atellica CH ECre\_2 and ECreJ assays will be updated to indicate that *‘Use of this assay is not recommended for patients undergoing treatment with phenindione, due to the potential for falsely depressed results’*.

## *Phenindione Interference with Atellica CH Enzymatic Creatinine\_2 and Japan Enzymatic Creatinine Assays*

The information related to phenindione provided in this letter supersedes the information in the current Atellica CH ECre\_2 and ECreJ IFUs until the IFUs are updated. It is anticipated that the IFU will be updated and available by April 2020.

### **Risk to Health**

Due to adverse side effects, phenindione is not widely prescribed. However, when creatinine is measured for a patient on phenindione therapy, the potential exists to report falsely depressed creatinine values that may lead to an underestimation of kidney disease and/or the misinterpretation of an increased estimated glomerular filtration rate (eGFR). Creatinine values are not used in isolation, but are correlated with clinical history and symptomology, as well as to other diagnostic laboratory testing such as blood urea nitrogen, electrolytes, albumin, and/or microalbumin. Discordance between these factors and the creatinine results would lead to questioning and further investigation. Siemens is not recommending a review of previously generated results.

### **Actions to be Taken by the Customer:**

- Please review this letter with your Medical Director.
- For patients on phenindione therapy an alternate Creatinine methodology (i.e. Jaffe Creatinine) is recommended.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

Please retain this letter with your laboratory records and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens technical support representative.

Atellica is a trademark of Siemens Healthcare Diagnostics.

**FIELD CORRECTION EFFECTIVENESS CHECK**

Phenindione Interference with the Atellica CH Enzymatic Creatinine\_2 and Japan Enzymatic Creatinine Assays

This response form is to confirm receipt of the enclosed Siemens Healthcare Diagnostics Urgent Field Safety Notice ACHC20-01.A.OUS dated December 2019 regarding Phenindione Interference with the Enzymatic Creatinine\_2 and Japan Enzymatic Creatinine Assays. Please read the question and indicate the appropriate answer. Return this completed form to Siemens Healthcare Diagnostics per the instructions provided at the bottom of this page.

1. I have read and understood the Urgent Field Safety Notice instructions provided in this letter. Yes  No

\_\_\_\_\_  
Name of person completing questionnaire:

\_\_\_\_\_  
Date:

\_\_\_\_\_  
Title:

\_\_\_\_\_  
Institution: Instrument Serial Number:

\_\_\_\_\_  
Street:

\_\_\_\_\_  
City: State:

\_\_\_\_\_  
Phone: Country:

\_\_\_\_\_  
Customer Sold To #: Customer Ship To #:

Please fax this completed form to the Customer Care Center at (###) ###-####. If you have any questions, contact your local Siemens technical support representative.